• HOME
  • INVESTMENTS
    • Equities >
      • Australia All Cap
      • Australia Small Cap Income
      • Global Mobility
      • Global High Conviction
    • Property >
      • Listed Property
      • TAMIM Property
    • Income >
      • Credit
  • INSIGHTS
    • Insights
    • Weekly Reading Lists
  • ABOUT
  • CONTACT
Tamim Asset Management
  • HOME
  • INVESTMENTS
    • Equities >
      • Australia All Cap
      • Australia Small Cap Income
      • Global Mobility
      • Global High Conviction
    • Property >
      • Listed Property
      • TAMIM Property
    • Income >
      • Credit
  • INSIGHTS
    • Insights
    • Weekly Reading Lists
  • ABOUT
  • CONTACT

Stock Insights

Stock Review - Our Investment in Pfizer

2/3/2016

0 Comments

 
At TAMIM Asset Management we speak to hundreds of DIY investors on a weekly basis, as they seek to achieve improved returns from their investment portfolio. A common theme we come across every week is where an investor has decided not to sell their shares due to capital gains tax implications. BHP seems to be one of the most common coming across our desk at present.
This is true for both business and portfolio investing, “Tax alone shouldn’t drive the decision.”

At Tamim, we speak to hundreds of DIY investors on a weekly basis, as they seek to achieve improved returns from their investment portfolio. A common theme we come across every week is where an investor has decided not to sell their shares due to capital gains tax implications. BHP seems to be one of the most common coming across our desk at present.

​

This week we discuss Pfizer and shed light on why making investment decisions based on a tax outcome as opposed to an investment outcome is not always optimal. We ask DIY investors reading this to reflect on any poor investment decisions made in the past that were a result of worrying too much about the effect of taking a capital gain. Prudent portfolio management is the key to long-term investment success. After all, you can’t go broke realising a profit.
Picture
The underlying fund for the Tamim Global Equity High Conviction IMA, managed by Robert Swift, has owned the global biopharmaceutical company Pfizer for a few years now, and as an investment it has been strong performer for the portfolio. It was originally an attractive investment due to the fact it was undervalued, but also for the following reasons:

  • Strong pipeline of drugs albeit mature – Lipitor (cholesterol), Viagra and Celebrex (anti inflammatory). These drugs were heavily geared to an aging population which is the current situation in the USA, and also that of the rest of the world which buys them
  • Acquisitions of Warner Lambert, Pharmacia and Wyeth in 2000’s all showed that the company could develop and buy growth. These acquisitions are getting harder (eg Astra Zeneca proposal was effectively blocked by UK politicians)
  • No material problems with governance or accounting
 
We are now at the point where we believe the risk/reward trade-off is no longer in our favour, and our proprietary VMQ score while still favourable is not at the attractive levels it was when we first entered the position. 
Picture
Pfizer operates in a sector facing common challenges. All pharmaceutical companies have an increasingly higher research and development (R&D) spend in order to come up with the next blockbuster drug. But that means more and more capital is at risk with each drug investment: i.e. the capital intensity is rising and it strikes us that many drug companies are looking more and more like car companies where it costs so much to develop a new car platform, that a failed model can jeopardise the whole business. Generics are also coming to market faster which erodes periods of super profitability for the established companies; and recently a political threat is now posed by Bernie Sanders and Hillary Clinton where we perceive both would be happy to bash the large US pharmaceutical companies.
 
Pfizer is also about to do a tax inversion deal. As we wrote in late 2015 as we pondered our investment:
“It has been widely documented that a key rationale of the Pfizer-Allergan mega merger is tax minimisation. By re-domiciling the company in Ireland, Allergan’s home, Pfizer will have the ability to avoid US taxes on $128bn of profits earned outside the United States.” A tactic commonly referred to as ‘tax inversion’.
 

Exploitation of this tax ‘loophole’, while great for potentially increasing shareholder value in the short term (and is not a sustainable way of growing earnings), presents a dilemma for the US government which has the authority to block the transaction. If they allow it to happen will we see a further rush of companies looking to follow in Pfizer’s footsteps? Or, could this deal be the catalyst for legislators to review and overhaul US corporate tax policy, acknowledging that high corporate taxes on USA based companies are not the way to encourage inward business investment?
Picture
Pfizer is not alone. Many multi-nationals in the US and UK are fed up with high costs, capricious regulations, and relatively higher taxes. It is not surprising that Pfizer are trying to minimise corporation tax since they already incur higher costs of doing business in the US including the funding of expensive healthcare and pension plans. Currently HSBC is ‘running the numbers’ on whether it should relocate to Hong Kong.

We are troubled by this deal not because of the tax benefits, but because it appears to be the only reason to do the deal. Corporate finance 101 taught us that the underlying purpose of a merger was to achieve a result of 1+1>2. Attempted tax arbitrage may fall into this category but for the wrong reasons. 

So, if the regulators and governments allow the merger to proceed, it is our view that Pfizer may have just bitten off more than they can chew…doing something for tax reasons alone is seldom a good reason.

This is true for both business and portfolio investing, “Tax alone shouldn’t drive the decision.”
​

The complexities associated with merging two companies of enormous size and differing cultures across multiple jurisdictions will alone present its own series of problems and if there are no true benefits to be ground out then it’s a deal that leaves us lukewarm.
Picture
Which is why prudent and active portfolio management is the key to long term investment success for any portfolio. After extracting some handsome gains in which we believe was a lower risk investment, Pfizer is now no longer a part of our investment portfolio and we will happily leave any further upside to the investor who was kind enough to take the stock off our hands.

The above scenario and resulting thought process is how we encourage you to think about your personal investments. If there are clouds gathering over a company within your portfolio, don’t ignore the warning signs as we are starting to see happening with Pfizer. This even more true if tax implications are the sole reason for your decision.
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Stock Commentary

    At TAMIM we are committed to educating investors on how best to manage their retirement futures.

    Sign up to receive our weekly newsletter:

    * indicates required

    TAMIM Asset Management provides general information to help you understand our investment approach. Any financial information we provide is not advice, has not considered your personal circumstances and may not be suitable for you.

    Archives

    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    December 2015

    Categories

    All
    2016 Presidential Election
    5G
    AGM Season
    Apple (AAPL.NASDAQ)
    Asia Small Companies
    ASX
    ATL.AX
    Aus Equity All Cap Portfolio
    Aus Equity All Cap Value Portfolio
    Aus Equity Growth Portfolio
    Aus Equity Income Portfolio
    Aus Equity Small Cap Portfolio
    Australian Stocks
    Autonomous Vehicles
    Big Four Banks
    Brexit
    Electric Vehicles
    Emerging Markets
    Energy
    ENN.AX
    FAANG
    Financials
    Fintech
    Global Equity High Conviction Portfolio
    Global Mobility
    Gmg.ax
    Gold
    Growth Stocks
    Guy Carson
    Healthcare
    Income Investing
    Infrastructure
    International Stocks
    Investment Thematics
    IT Services
    Mergers & Acquisitions
    Mobility
    Pharma
    Property
    Rare Earths
    REITs
    Reporting Season
    Retail
    Robert Swift
    Ron Shamgar
    SLK.AX
    Small Cap Income Portfolio
    Small Caps
    Stock Report
    Takeovers
    Technology
    Telco Stocks
    Telstra (TLS.ASX)
    Tourism
    TPG
    Utilities
    Value Investing
    Video
    Wesfarmers (WES.ASX)

    RSS Feed

TAMIM | Equities | Property | Credit
​

TAMIM Fund
Australia All Cap
Australia Small Cap Income
Global Mobility
Global High Conviction
Credit

Listed Property
TAMIM Property
Company
About
Contact
Insights
Invest Online
Login
Other
Privacy Policy
Terms & 
Conditions
​Disclaimer
Contact
Level 4, 55 Grafton Street
Bondi Junction, Sydney NSW, 2022

1300 750 007

ima@tamim.com.au

DISCLAIMER

​The information provided on this website should not be considered financial or investment advice and is general information intended only for wholesale clients ( as defined in the Corporations Act). If you are not a wholesale client, you should exit the website. The content has been prepared without taking into account your personal objectives, financial situations or needs. You should seek personal financial advice before making any financial or investment decisions. Where the website refers to a particular financial product, you should obtain a copy of the relevant product services guide or offer document for wholesale investors before making any decision in relation to the product. Investment returns are not guaranteed as all investments carry some risk. The value of an investment may rise or fall with the changes in the market. Past performance is no guarantee of future performance. This statement relates to any claims made regarding past performance of any Tamim (or associated companies) products. Tamim does not guarantee the accuracy of any information in this website, including information provided by third parties. Information can change without notice and Tamim will endeavour to update this website as soon as practicable after changes. Tamim Funds Management Pty Limited and CTSP Funds Management Pty Ltd trading as Tamim Asset Management and its related entities do not accept responsibility for any inaccuracy or any actions taken in reliance upon this advice. All information provided on this website is correct at the time of writing and is subject to change due to changes in legislation. Please contact Tamim if you wish to confirm the currency of any information on the website.  

magellen, kosec, clime, wilson, wam, montgomery, platinum, commsec, caledonia, pengana, tamim

  • HOME
  • INVESTMENTS
    • Equities >
      • Australia All Cap
      • Australia Small Cap Income
      • Global Mobility
      • Global High Conviction
    • Property >
      • Listed Property
      • TAMIM Property
    • Income >
      • Credit
  • INSIGHTS
    • Insights
    • Weekly Reading Lists
  • ABOUT
  • CONTACT